Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureElisabeth McClymont, Sandra Blitz, Sofia Nicolls, Marette Lee, François Coutlée, Sharon Walmsley, Sylvie Trottier, Fiona Smaill, Mona Loutfy, Mark H Yudin, Marina B Klein, Marianne Harris, Sarah Stone, Jorge L Martinez-Cajas, Deborah Money, Arianne Albert, Ariane Alimenti, Arezou Azampanah, Ari Bitnun, Jason Brophy, Jan Christilaw, Jeffrey Cohen, Andrew Coldman, Simon Dobson, Catherine Hankins, Christos Karatzios, Mel Krajden, Normand Lapointe, Nancy Lipsky, Jessica McAlpine, Dianne Miller, Erin Moses, Dirk Van Niekerk, Gina Ogilvie, Neora Pick, Janet Raboud, Lindy Samson, Julie Van Schalkwyk, David Scheifele, Joel Singer, Gavin Stuart, Marcie Summers, Laura Vicol, Melissa Watt
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The epidemiology of human papillomavirus infections
10.1016/j.jcv.2004.12.008 · 2005
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse)
2001
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
10.1002/(sici)1096-9896(199909)189:1<12::aid-path431>3.0.co;2-f · 1999
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
10.1038/bjc.2011.185 · 2011
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
10.1016/s1470-2045(11)70286-8 · 2012
Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women
10.1371/journal.pone.0083431 · 2013
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women
10.1093/jnci/djp534 · 2010
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
10.1016/j.vaccine.2006.04.068 · 2006
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
10.1016/s0140-6736(17)31821-4 · 2017
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
10.1016/s1470-2045(05)70101-7 · 2005
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
10.1016/j.vaccine.2008.09.073 · 2008
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial
10.1016/s0140-6736(09)60691-7 · 2009
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries
10.1016/j.eclinm.2020.100401 · 2020
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
2018
The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis
10.1186/s12889-020-08753-y · 2020
HIV infection and survival among women with cervical cancer
10.1200/jco.2016.67.9613 · 2016
HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine
10.1016/j.vaccine.2016.08.016 · 2016
The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with human immunodeficiency virus
10.1093/cid/ciy575 · 2019
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in girls living with HIV
10.1097/inf.0000000000001874 · 2018
Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test
10.1128/jcm.00104-06 · 2006
Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test
10.1128/jcm.01145-07 · 2007
Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models
10.1111/j.1467-9868.2010.00749.x · 2010
Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging
10.1016/s1470-2045(15)70075-6 · 2015
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine—a combined analysis of five phase III clinical trials
10.1016/j.pvr.2017.03.002 · 2017
Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials
10.1086/599988 · 2009
Immunogenicity and safety of two versus three doses of 9-valent vaccine against Human papillomavirus (HPV) in women with HIV: the Papillon randomized trial
2025
Population impact of South Africa's human papillomavirus (HPV) vaccination programme on HPV prevalence in adolescent girls with and without HIV: a repeat cross-sectional study
10.1016/s2214-109x(25)00525-x · 2026
No additional external references are available.